How Nimbus will use $210M round to chase multiple targets, therapeutic areas

A new $210 million equity round that adds GV to Nimbus’ investor syndicate will strengthen the biotech’s balance sheet as it aims to advance multiple programs across three large therapeutic areas, including a clinical molecule targeting HPK1 for solid tumors.

The deal prepares 14-year-old Nimbus Therapeutics LLC for more clinical and preclinical work, less than a year after it sold a TYK2 program to Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) for $4 billion. That deal, structured as the sale of asset-centric subsidiary Nimbus Lakshmi Inc., rewarded the biotech’s shareholders with a handsome return...